3/13/2012

The FDA is seeking public comment on guidance detailing a system for handling postmarket drug safety issues, including drug quality and serious adverse events. The draft guidance establishes a three-tiered system of classifying the severity of problems.

Full Story:
PMLive.com (U.K.)

Related Summaries